Follow The Filings

INDV Indivior Pharmaceuticals Inc.

Health Care, filed as INDIVIOR PHARMACEUTICALS INC (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 1 Owner
  • Max 3.5%
  • $251M
  • 1 reduce 1 exit

In 2026 Q2 Howard Marks trimmed Indivior Pharmaceuticals, and Michael Krensavage sold out.

Who owns this now

Largest portfolio weights among holders, up to 3.5% (Howard Marks, Oaktree Capital Management). Not free-float ownership.

  1. Howard Marks Reduce 3.5%

Who owns INDV

Sorted by value, long equity only, as of 2026 Q2.

History
Howard Marks, Oaktree Capital Management 3.5% Reduce −12.3% 6,127,212 $251M History
Michael Krensavage, Krensavage Asset Management exited 2026 Q2 Last 2026 Q1 4.1% Exit −4.05% 339,532 $10M History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by INDV's executives, directors and 10% owners in the last 12 months, from their Form 4s

All INDV insider trades
  • $312K bought by 7 insiders
  • None no sales outside a trading plan
  • $2.8M sold by 2 insiders under 10b5-1 plans
  1. Woodrow D Anderson Chief Accounting Officer
    Buy
    $54K 1,500 shares at $35.69 +5.7% to stake
    Traded Aug 27 Filed Aug 27
    ↗
  2. Woodrow D Anderson Chief Accounting Officer
    Buy
    $54K 1,500 shares at $36.28 +6.1% to stake
    Traded Aug 5 Filed Aug 5
    ↗
  3. Christian Heidbreder Chief Scientific Officer
    Planned sale
    $765K 18,586 shares at $41.14 8.2% of stake
    Traded Jul 10 Filed Jul 13
    ↗
  4. Christian Heidbreder Chief Scientific Officer
    Planned sale
    $707K 18,586 shares at $38.06 7.5% of stake
    Traded Jun 11 Filed Jun 12
    ↗
  5. Ryan Preblick CFO
    Planned sale
    $1.4M 36,000 shares at $37.70 11% of stake
    Traded Jun 8 Filed Jun 10
    ↗
  6. Barbara Ryan Director
    Buy
    $249 8 shares at $31.09 +0.1% to stake
    Traded Mar 13 Filed Mar 13
    ↗
  7. Barbara Ryan Director
    Buy
    $1,009 31 shares at $32.56 +0.5% to stake
    Traded Mar 9 Filed Mar 11
    ↗
  8. Stuart A Kingsley Director
    Buy
    $30K 940 shares at $31.87 +20% to stake
    Traded Mar 6 Filed Mar 11
    ↗
  9. Keith Humphreys Director
    Buy
    $27K 775 shares at $35.39 +15% to stake
    Traded Jan 5 Filed Jan 7
    ↗
  10. David E. Wheadon Director
    Buy
    $63K 1,771 shares at $35.39 +14% to stake
    Traded Jan 5 Filed Jan 7
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 stock grants, 8 share withholdings for taxes, and 7 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.07 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 1.02,9.01 Filing Doc
424B3 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,1.02,2.03,3.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Revenue $1.19B $1.24B
Gross profit $957M $994M
Gross margin * 80.6% 80.2%
Net income $2M $210M
Net margin * 0.2% 16.9%

Balance sheet

Metric FY2024 FY2025
Total current assets $839M $652M
Total non-current assets * $480M $549M
Total assets $1.32B $1.2B
Total current liabilities $939M $914M
Total non-current liabilities * $729M $386M
Total equity -$348M -$98M

Cash flow

Metric FY2024 FY2025
Cash from operations $36M -$27M
Cash from investing $69M -$66M
Cash from financing -$102M -$30M
Net change in cash * $3M -$123M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.